214 related articles for article (PubMed ID: 23108403)
1. RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.
Ray-David H; Romeo Y; Lavoie G; Déléris P; Tcherkezian J; Galan JA; Roux PP
Oncogene; 2013 Sep; 32(38):4480-9. PubMed ID: 23108403
[TBL] [Abstract][Full Text] [Related]
2. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
3. P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation.
Li P; Goto H; Kasahara K; Matsuyama M; Wang Z; Yatabe Y; Kiyono T; Inagaki M
Mol Biol Cell; 2012 Apr; 23(8):1582-92. PubMed ID: 22357623
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
[TBL] [Abstract][Full Text] [Related]
5. RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth.
Romeo Y; Moreau J; Zindy PJ; Saba-El-Leil M; Lavoie G; Dandachi F; Baptissart M; Borden KLB; Meloche S; Roux PP
Oncogene; 2013 Jun; 32(24):2917-2926. PubMed ID: 22797077
[TBL] [Abstract][Full Text] [Related]
6. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling.
Abe Y; Yoon SO; Kubota K; Mendoza MC; Gygi SP; Blenis J
J Biol Chem; 2009 May; 284(22):14939-48. PubMed ID: 19332537
[TBL] [Abstract][Full Text] [Related]
7. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
[TBL] [Abstract][Full Text] [Related]
8. Proteomic Analysis Reveals a Role for RSK in p120-catenin Phosphorylation and Melanoma Cell-Cell Adhesion.
Méant A; Gao B; Lavoie G; Nourreddine S; Jung F; Aubert L; Tcherkezian J; Gingras AC; Roux PP
Mol Cell Proteomics; 2020 Jan; 19(1):50-64. PubMed ID: 31678930
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.
Roux PP; Richards SA; Blenis J
Mol Cell Biol; 2003 Jul; 23(14):4796-804. PubMed ID: 12832467
[TBL] [Abstract][Full Text] [Related]
10. Bub1 is activated by the protein kinase p90(Rsk) during Xenopus oocyte maturation.
Schwab MS; Roberts BT; Gross SD; Tunquist BJ; Taieb FE; Lewellyn AL; Maller JL
Curr Biol; 2001 Feb; 11(3):141-50. PubMed ID: 11231148
[TBL] [Abstract][Full Text] [Related]
11. P90 ribosomal S6 kinase confers cancer cell survival by mediating checkpoint kinase 1 degradation in response to glucose stress.
Ma Y; Cui D; Wang L; Wang Y; Yang F; Pan H; Gong L; Zhang M; Xiong X; Zhao Y
Cancer Sci; 2022 Jan; 113(1):132-144. PubMed ID: 34668620
[TBL] [Abstract][Full Text] [Related]
12. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
[TBL] [Abstract][Full Text] [Related]
13. Novel potent and selective inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven cancers.
Aronchik I; Appleton BA; Basham SE; Crawford K; Del Rosario M; Doyle LV; Estacio WF; Lan J; Lindvall MK; Luu CA; Ornelas E; Venetsanakos E; Shafer CM; Jefferson AB
Mol Cancer Res; 2014 May; 12(5):803-12. PubMed ID: 24554780
[TBL] [Abstract][Full Text] [Related]
14. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
15. Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM/p53/p21 pathway is functional.
Lossaint G; Besnard E; Fisher D; Piette J; Dulić V
Oncogene; 2011 Oct; 30(41):4261-74. PubMed ID: 21532626
[TBL] [Abstract][Full Text] [Related]
16. Paving the way for targeting RSK in cancer.
Romeo Y; Roux PP
Expert Opin Ther Targets; 2011 Jan; 15(1):5-9. PubMed ID: 20958120
[TBL] [Abstract][Full Text] [Related]
17. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
18. UV-induced G2 checkpoint depends on p38 MAPK and minimal activation of ATR-Chk1 pathway.
Warmerdam DO; Brinkman EK; Marteijn JA; Medema RH; Kanaar R; Smits VA
J Cell Sci; 2013 May; 126(Pt 9):1923-30. PubMed ID: 23447674
[TBL] [Abstract][Full Text] [Related]
19. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation.
Carrière A; Cargnello M; Julien LA; Gao H; Bonneil E; Thibault P; Roux PP
Curr Biol; 2008 Sep; 18(17):1269-77. PubMed ID: 18722121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
